A small proportion of glioblastoma patients are probably eligible for concomitant/adjuvant temozolomide.
O'Toole
L
L
Khanduri
S
S
Gerrard
G E
GE
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000628:therapy*; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D005909:Glioblastoma / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D017410:Practice Guidelines as Topic; D013222:State Medicine; D000077204:Temozolomide; D006113:United Kingdom
D000276:Adjuvants, Immunologic; D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide